News | February 17, 2025
Sanofi updates on extraintestinal pathogenic E. coli vaccine phase 3 clinical study
No safety signals related to the vaccine candidate were identified
No safety signals related to the vaccine candidate were identified
The safety profile of Opdualag observed in this analysis was consistent with the known profiles of nivolumab and relatlimab
He also laid the foundation stone for a state-of-the-art 50-bedded Critical Care Block (CCB)
Accelerated approval is based on 61% overall response rate compared to 40% in control arm in the
Emraclidine was well-tolerated with an adverse event profile consistent with Phase 1b trial
These initiatives signify a substantial boost to healthcare infrastructure across India, aligned with the Prime Minister’s mission of ensuring quality healthcare services nationwide
This partnership will enable healthcare organizations to provide best-in-class patient/consumer experiences
Gilead Sciences first launched Lenacapavir under the brand name Sunlenca in the United States and Europe markets in the year 2022
Based out of Boston, Vivek will build on the foundation created by Vaidheesh, and will help build a stronger customer connect and further drive global expansion of the platform
The partnership will provide health plans with an out-of-the-box compliance solution for CMS-9115 and CMS-0057 rules
Subscribe To Our Newsletter & Stay Updated
